Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended June 30, 2016, and the nine-month period ending on that date. The registrant is an Australian biotechnology entity admitted on the basis of commitments, reporting under Rule 4.7B Appendix 4C. The filing was signed on July 27, 2016.
Key Financial Metrics
Cash Flow (Quarter Ended June 30, 2016):
- Net Operating Cash Flows: $3,122,000 AUD (Positive)
- Net Investing Cash Flows: $0 AUD
- Net Financing Cash Flows: $0 AUD
- Net Increase in Cash: $3,122,000 AUD
- Cash at End of Quarter: $28,594,000 AUD
Cash Flow (Nine Months Ended June 30, 2016):
- Net Operating Cash Flows: $(7,420,000) AUD (Negative)
- Net Investing Cash Flows: $(2,000) AUD
- Net Decrease in Cash: $(7,422,000) AUD
Operating Expenses (Quarter):
- Research and Development: $(2,234,000) AUD
- Staff Costs: $(683,000) AUD
- Other Working Capital: $(426,000) AUD
- Advertising and Marketing: $(20,000) AUD
Revenue and Profit: The filing text does not provide a clear value for revenue or net profit. Receipts from customers are listed as zero. The positive operating cash flow for the quarter is primarily driven by "Other (Grants/Donations)" of $6,461,000 AUD.
Debt and Liquidity: No borrowings, repayments, or loan facilities are reported. Cash and deposits at call total $28,594,000 AUD.
Material Changes
The most significant change is the shift in operating cash flow from a deficit of $7.42 million over the nine-month period to a surplus of $3.12 million in the current quarter. This reversal is attributable to a substantial grant or donation receipt of $6.46 million in the quarter, offsetting operating expenditures of approximately $3.36 million. There were no acquisitions, disposals, or equity issuances during the period.
Guidance, Outlook, and Risks
The filing contains no specific guidance, forward-looking statements, or management commentary regarding future outlook. No risks or contingencies are explicitly detailed in the provided text. The entity reports no non-cash financing activities and no related party loans outstanding.
Investor Verification Checklist
- Verify the nature and sustainability of the $6.46 million grant/donation received in the quarter.
- Confirm the company's cash burn rate excluding grant income, given the $9.04 million R&D spend over nine months.
- Review the status of the company's pipeline and development milestones, as no revenue is currently generated.
- Check for any subsequent capital raising activities post-June 30, 2016, given the lack of financing in this period.